Bayer's Ask Bio unit starts Phase II heart failure gene therapy
Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
German companies to revolutionise lab plastics market
/in News/by Thomas GabrielczykGerman Green Elephant Biotech has launched the world's first plant-based 96-well microtitre plate on the market.
AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases
/in News/by Thomas GabrielczykBelfast-based techbio company<b> </b>AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform.
Cambridge university spin-out HutanBio Ltd bags £2.25m seed financing
/in News/by Thomas GabrielczykBritish-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water.<br /><br /><br />
EU parliament votes in favour of New Genome Techniques
/in News/by Thomas GabrielczykThe European Parliament adopted its position for negotiations with Member States on the Commission's proposal on new genomic techniques (NGTs) in favour for using CRISPR/Cas as a new but now […]
EU parliament backs deregulation of New Genome Techniques
/in News/by Thomas GabrielczykAfter two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.<br /> <br /><br /> <br /><br […]
Jazz Pharmaceiticals licences KRAS blocker from Redx Pharma
/in News/by Thomas GabrielczykJazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
/in News/by Thomas GabrielczykJazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />
Spanish plant-based protein producer Heura closes Series B financing
/in News/by Thomas GabrielczykSpanish Food tech Start-up Heura Foods secures €40m in Series B financing round to expand product distribution.<br /><br /><br />
Spanish plant-based protein producer Heüra Foods closes Series B financing
/in News/by Thomas GabrielczykSpanish Food tech Start-up Heüra Foods secures €40m in Series B financing round to expand product distribution.<br /><br /><br />